Literature DB >> 22533537

Salivary cortisol, 17β-estradiol, progesterone, dehydroepiandrosterone, and α-amylase in patients with burning mouth syndrome.

H-Il Kim1, Y-Y Kim, J-Y Chang, J-Y Ko, H-S Kho.   

Abstract

OBJECTIVE: The aim of this study was to investigate salivary markers related with burning mouth syndrome (BMS).
MATERIALS AND METHODS: Thirty female patients with BMS and twenty female control subjects were included. Unstimulated (UWS) and stimulated whole saliva samples (SWS) were collected, and their flow rates were determined. Salivary levels of cortisol, 17β-estradiol, progesterone, dehydroepiandrosterone (DHEA), and enzymatic activity of α-amylase were determined. Salivary transferrin level was measured to determine the level of blood contamination in saliva samples.
RESULTS: The levels of all analytes in UWS were significantly correlated with those of SWS. The levels of 17β-estradiol, progesterone, and DHEA in UWS were significantly correlated with age. Age-matched comparisons revealed that the patient group had significantly higher levels of cortisol in UWS and of 17β-estradiol in SWS. When the patients were divided into older (≥60years) and younger (<60years) groups, the older group showed a significantly lower level of progesterone in UWS. There were no significant relationships between treatment efficacy and levels of salivary analytes.
CONCLUSIONS: In conclusion, patients with BMS showed significantly higher levels of cortisol in UWS and of 17β-estradiol in SWS compared with controls.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22533537     DOI: 10.1111/j.1601-0825.2012.01937.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  8 in total

1.  The utility and dynamics of salivary sex hormone measurements in the National Social Life, Health, and Aging Project, Wave 2.

Authors:  Michael J Kozloski; L Philip Schumm; Martha K McClintock
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2014-11       Impact factor: 4.077

2.  Opiorphin in burning mouth syndrome patients: a case-control study.

Authors:  Ivan Salarić; Maja Sabalić; Ivan Alajbeg
Journal:  Clin Oral Investig       Date:  2016-12-24       Impact factor: 3.573

3.  Response to Treatment with Melatonin and Clonazepam versus Placebo in Patients with Burning Mouth Syndrome.

Authors:  Candela Castillo-Felipe; Asta Tvarijonaviciute; Marina López-Arjona; Luis Pardo-Marin; Eduardo Pons-Fuster; Pia López-Jornet
Journal:  J Clin Med       Date:  2022-04-29       Impact factor: 4.964

4.  Salivary Alpha-Amylase Enzyme, Psychological Disorders, and Life Quality in Patients with Recurrent Aphthous Stomatitis.

Authors:  Juliana Andrade Cardoso; André Avelino Dos Santos Junior; Maria Lucia Tiellet Nunes; Maria Antonia Zancanaro de Figueiredo; Karen Cherubini; Fernanda Gonçalves Salum
Journal:  Int J Dent       Date:  2017-03-19

5.  Salivary Cortisol Levels and Burning Symptoms in Patients with Burning Mouth Syndrome before and after Low Level Laser Therapy: a Double Blind Controlled Randomized Clinical Trial.

Authors:  Ivana Škrinjar; Božana Lončar Brzak; Valentina Vidranski; Vanja Vučićević Boras; Ana Andabak Rogulj; Božidar Pavelić
Journal:  Acta Stomatol Croat       Date:  2020-03

Review 6.  Protein-Based Salivary Profiles as Novel Biomarkers for Oral Diseases.

Authors:  Alejandro I Lorenzo-Pouso; Mario Pérez-Sayáns; Susana B Bravo; Pía López-Jornet; María García-Vence; Manuela Alonso-Sampedro; Javier Carballo; Abel García-García
Journal:  Dis Markers       Date:  2018-11-07       Impact factor: 3.434

7.  Burning Mouth Syndrome: A Comparative Cross-sectional Study.

Authors:  Maryam Rabiei; Ehsan Kazemnezhad Leili; Leili Alizadeh
Journal:  Contemp Clin Dent       Date:  2018-09

8.  Salivary Biomarkers and Their Correlation with Pain and Stress in Patients with Burning Mouth Syndrome.

Authors:  Pia Lopez-Jornet; Candela Castillo Felipe; Luis Pardo-Marin; Jose J Ceron; Eduardo Pons-Fuster; Asta Tvarijonaviciute
Journal:  J Clin Med       Date:  2020-03-28       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.